TABLE I.

Clinical and demographic information for the three groups

	LTLE	RTLE	Controls
N	21	23	28
Age	42.5±13.6	36.4±14.5	39.3±13.3
Gender F/M	15/7	10/13	21/7
Intracranial Volume (Liters)	1.35±0.23	1.48±0.27	1.52±0.18
Edinburgh Handedness	87±44	78±57	76±53
W/o Right Arcuate	13/8	19/4	25/3
Full Scale IQ	91±13.8	96±10.4	n/a
Age at epilepsy onset	19±16.1	22±12.1	n/a
Duration of Epilepsy	24±19.1	15±12.3	n/a
Seizure Types (no. of patients)	13 – CPS only 2 – CPS + GTCS 1 – SPS only 1 – CPS w/2° GTCS 3 – CPS + SPS 0 – CPS w/2° GTCS + SPS	12 – CPS only 4 – CPS + GTCS 0 – SPS only 3 – CPS w/2° GTCS 3 – CPS + SPS 1 – CPS w/2° GTCS + SPS
MTS/non-MTS (no. of patients)	11/10	9/14	n/a
Sugery	14 (67%)  12 – ATL  1 – laser ablation  1 – gamma knife	14 (61%)  14 – ATL
Seizure-free post-surgery	12 (86%) range: 14–72 months post-op	9 (64%) range: 8–48 months post-op
Medication (no. of patients)	4 – Carbamazepine 1 – Depakote 2 – Lacosamide 7 – Lamotrigine 10 – Levetiracet 1 – Oxcarbazepine 2 – Phenobarbital 3 – Topiramate 2 – Zonisamide 5 – Other	4 – Carbamazepine 3 – Depakote 5 – Lacosamide 4 – Lamotrigine 12 – Levetiracet. 4 – Oxcarbazepine 1 – Phenobarbital 3 – Topiramate 3 – Zonisamide 6 – Other

Abbreviations: MTS=mesial temporal sclerosis, CPS=complex partial seizures, GTCS=generalized tonic-clinic seizures, SPS=simple partial sizures, w/2° GTCS=with secondary generalization.